Chdi Foundation, Inc.

Aventis Pharmaceuticals Inc.

Regeneron Pharmaceuticals, Inc.

Douglas Macdonald

Celia Dominguez

Gavin Thurston

Gang Chen

Joel H Martin

Stephen Martin Courtney

John Wityak

Michael Edward Prime

Richard Waldron Marston

Samuel H Davis

Raymond W Kosley, Jr

Frederick Arthur Brookfield

Tammy T Huang

Thomas Nittoli

Eric B Smith

Frank Delfino

Robert Babb

Marcus Kelly

Lauric Haber

Christopher John Yarnold

Mark W Sleeman

Xunbao Duan

Rosy Sher

Jessica R Kirshner

Kara Louise Olson

Christopher Daly

Eric Smith

Certain compounds and pharmaceutically acceptable salts are provided herein. Also provided are pharmaceutical compositions comprising at least one compound or pharmaceutically acceptable salt therein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain disease states responsive to the inhibition of transglutaminase TG2 activity are described. These disease states include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one compound or pharmaceutically acceptable salt thereof as a single active agent or administering at least one compound or pharmaceutically acceptable salt thereof in combination with one or more other therapeutic agents.

Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof

The present invention is directed to dipyrazole compounds of formula I and their pharmaceutically acceptable salts, stereoisomers, tautomers, or solvates thereof. Novel compounds include those of formula I.  The compounds of this invention modulate AMPA and NMDA receptor function, and therefore are useful as pharmaceutical agents, especially for the treatment of neuropsychiatric disorders.

Dipyrazole compounds and their use as central nervous system agents

Growing community of inventors

Los Angeles, CA, United States of America

Douglas Macdonald